β οΈ Clozapine can cause severe gastrointestinal hypomotility β constipation, faecal impaction,
intestinal obstruction, and paralytic ileus (rare but potentially fatal). Treat constipation as a medical priority.
About
-
π Always confirm indication, dosing, monitoring requirements, interactions, and counselling in the
BNF clozapine monograph.
- π©Ί Specialist initiation only; ensure the patient is registered with the clozapine monitoring service (UK).
- β€οΈ Baseline: BP (postural), pulse, weight/BMI/waist, glucose/HbA1c, lipids, LFTs; consider baseline ECG (local policy).
-
π¦ Counsel on neutropenia red flags: fever, flu-like symptoms, sore throat, mouth ulcers β
seek urgent assessment and blood count.
-
π½ Ask about bowels at every review: frequency, stool consistency, abdominal pain, vomiting, bloating β
escalate urgently if red flags (no flatus, severe pain, persistent vomiting).
Mode of action
- π§ Atypical antipsychotic with broad receptor antagonism: D2 (relatively weak/fast dissociation), 5-HT2A, plus
Ξ±1 and muscarinic effects (drives hypotension, sedation, anticholinergic GI hypomotility).
Indication
- π§© Primary licensed use: treatment-resistant schizophrenia (specialist care).
- π§ In some settings, used at low dose for psychosis in Parkinsonβs disease under specialist supervision (very cautious titration).
Dose (Parkinsonβs disease psychosis β specialist, low-dose approach)
- π Start 12.5 mg at bedtime.
- β¬οΈ Increase by 12.5 mg increments (often no more than twice weekly initially; slower if frail/PD autonomic symptoms).
- π― Typical effective dose is often 25β50 mg/day (usually at night); keep dose as low as possible.
- β Max is commonly kept to 50 mg/day in PD (higher doses only in exceptional specialist cases).
Key prescribing advice
- π©Έ Blood monitoring is non-negotiable: clozapine cannot be supplied without compliant FBC/ANC monitoring.
-
π¬ Smoking matters: cigarette smoke induces CYP1A2 β lowers clozapine levels; sudden smoking cessation can raise levels and toxicity risk.
- β Caffeine changes can also affect levels (advise consistent intake).
- π§ Seizure risk rises with dose and rapid titration; avoid abrupt dose jumps.
Haematology monitoring (typical UK schedule)
- π
Weekly FBC for the first 18 weeks, then fortnightly up to 1 year, then 4-weekly if stable (and continue monitoring for 4 weeks after stopping).
- π¨ If significant neutropenia occurs, stop clozapine and follow the monitoring service / haematology pathway (thresholds depend on the service and whether BEN applies).
- π Benign ethnic neutropenia (BEN): initiation/continuation may be possible under agreed specialist criteria.
GI hypomotility / constipation prevention
- π§» Record baseline bowel habit and start a proactive plan (often stool softener + stimulant laxative per local policy).
- π§ Encourage fluids and mobility where feasible; review constipating co-meds (opioids, antimuscarinics, iron).
- π Red flags needing urgent same-day assessment: severe/colicky abdominal pain, persistent vomiting, abdominal distension, no stool/flatus, fevers.
Cautions
- β€οΈ Cardiac disease, history of myocarditis/cardiomyopathy, QTc concerns (riskβbenefit + monitoring plan).
- β‘ Seizure disorder, dementia/frailty (sedation/falls), autonomic dysfunction (postural hypotension).
- π¬ Diabetes/metabolic risk (weight gain, dysglycaemia, lipids).
- ποΈ Glaucoma risk, prostatic symptoms/urinary retention (anticholinergic effects).
Contraindications
- β See BNF for full list (including prior clozapine-associated agranulocytosis and situations where monitoring cannot be assured).
Interactions (high-yield)
- π Full list: see BNF.
- π« Avoid/add extreme caution with other drugs that affect white cells (e.g. carbamazepine).
- π§ͺ CYP interactions: inhibitors (e.g. fluvoxamine, ciprofloxacin) can β levels; inducers (incl. smoking) β levels.
- π€ Additive sedation/hypotension with CNS depressants, benzodiazepines, alcohol.
Notable adverse effects
- π¦ Neutropenia/agranulocytosis (potentially fatal) β strict monitoring + urgent response to infection symptoms.
- π¨ Myocarditis (often early weeks) and cardiomyopathy (later) β watch for chest pain, dyspnoea, tachycardia, fever.
- π½ Constipation/ileus from GI hypomotility (treat proactively).
- π΄ Sedation, hypersalivation, postural hypotension, seizures (dose/titration related), weight gain/metabolic syndrome.
References
Revisions